As a reliable marker of systemic inflammation, CRP levels have been observed to be associated with all features of the metabolic syndrome including abdominal obesity, hypertension, hyperglycemia and/or hyperinsulinemia, and dyslipidemia (high triglyceride-low HDL cholesterol). Regardless of diverse definitions used for the metabolic syndrome in different studies, there is an emerging consensus that CRP levels are also associated with the presence of metabolic syndrome itself as an entity. Earlier cross-sectional studies reported elevated levels of various inflammatory markers in diabetic patients with features of the metabolic Table 1 ). These cross-sectional analyses clearly showed that elevated CRP levels correlate significantly with features of the metabolic syndrome using either strict NCEP-ATP III criteria or modified NCEP-based definitions. In addition, several cross-sectional studies had observed gender-specific association between CRP levels and the metabolic syndrome. 5 Such gender-based differences may indicate an underlying interrelationship between sex hormones and the proinflammatory response, although greater adiposity and larger sample size in women than men could, at least in part, explain such sex-differences.
Although prospective data are limited, the available evidence parallels the findings from cross-sectional studies, suggesting that low-grade chronic inflammation, as indicated by CRP levels, contributes to the development of metabolic syndrome. 6 Beyond the assessment of the metabolic syndrome, CRP has been shown to improve the clinical risk assessment to predict future risk of developing CVD and type 2 diabetes in prospective observational studies. 5, 7, 8 Overall, epidemiologic data provide a clear message that addition of CRP as a criterion for the diagnosis of metabolic syndrome may add more prognostic information. Adding it formally to the metabolic syndrome definition could improve our ability to identify high-risk patients in both primary and secondary prevention. However, most studies have been crosssectional and were unable to fully account for residual confounders, particularly obesity or insulin resistance, leaving unresolved the independent values of CRP measurement for predicting CVD and type 2 diabetes. There is a notable lack of data from prospective studies regarding the practical clinical and public health significance of incorporating CRP measurements into the metabolic syndrome definition. Although careful consideration should be given to the clinical value of adding CRP, more research in this area is needed. From a clinical perspective, physicians should continue to focus on evaluating and treating individuals based on traditional risk factors. 
